Agios Pharmaceuticals | AGIO - Le Bénéfice D'Exploitation





Le Bénéfice D'Exploitation Changement Date
AbbVie USD 4.73B 1.08B 2026-03
Agios Pharmaceuticals USD -110.02M 11.55M 2026-03
Alnylam Pharmaceuticals USD 29.4M 59.36M 2025-12
Amgen USD 3.96B 464M 2025-12
Arrowhead Research USD 40.81M 3.3M 2025-12
Astellas Pharma JPY 48.57B 85.97B 2026-03
AstraZeneca USD 7.11B 4.14B 2026-03
Bayer EUR 1.11B 1.65B 2025-12
Biogen USD 514.3M 128.8M 2026-03
BioMarin Pharmaceutical USD 198.39M 230.08M 2025-12
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Daiichi Sankyo JPY 89.54B 42.01B 2025-12
Eli Lilly USD 8.99B 599.9M 2025-12
Exelixis USD 235.91M 20.45M 2025-12
Gilead Sciences USD 2.96B 551M 2025-12
GlaxoSmithKline GBP 2.29B 856M 2026-03
Incyte USD 383.88M 47.43M 2025-12
Ionis Pharmaceuticals USD -118M 97M 2026-03
Merck USD 6.24B 318M 2025-12
Moderna USD -857M 597M 2025-12
Nektar Therapeutics USD -19.09M 15.26M 2025-12
Novartis USD 4.24B 171M 2026-03
Novartis USD 4.06B 521M 2025-12
Pfizer USD 4.65B 3.99B 2025-12
Puma Biotechnology USD 22.08M 24.26M 2024-09
Regeneron Pharmaceuticals USD 744.8M 153.8M 2026-03
Roche Holding CHF 9.56B 3.8B 2025-12
Sarepta Therapeutics USD -410.08M 347.2M 2025-12
Vertex Pharmaceuticals USD 1.26B 24.5M 2025-12